All News
Giblo et al, 1000+ pop-based cohort RA:
Cumulative incidence of depression =
Increase in cumulative incidence of anxiety 2005–14 vs. earlier decades
Despite improvements in RA ttmts. Maybe time we address these separately?
https://t.co/Z3FUgSETKW
Abs#0889 #ACR22 @Rheumnow https://t.co/Rn2ru80021
Aurelie Najm AurelieRheumo ( View Tweet)
Kang @karen_kc123 et al ≥ 20 pack-years cigarette smoking associated with higher risk of incident PMR in women (HR 1.46). Every 10 pack-years associated 9% increase in risk @RheumNow #ACR22 Abstr#0698 https://t.co/t51fKFs7iJ https://t.co/IS9XC9DXl8
Richard Conway RichardPAConway ( View Tweet)
Maguire @Sineadm15 @rheum_covid (and me!) obstetric outcomes in RMD and COVID-19. Unvaccinated higher freq pre-term birth. Regardless of vaccine status, the women themselves did well, rarely needing pharmacotherapy @RheumNow #ACR22 Abstr#0950 #ACRbest https://t.co/GLMAAvbC4a https://t.co/kpXZbRSoMo
Richard Conway RichardPAConway ( View Tweet)
DIPSA: RCT in PsA pts w/ BMI > 25 Mediterranean diet vs. DASH-low caloric diet vs. SoC
BL: 72% obese, 42% dyslipidemia, 38% HBP, MetS 47%
Looking forward to seeing the results of this dietary intervention, MetS is high in PsA!
https://t.co/29Aq0TLANO
Abs#1007 #ACR22 @Rheumnow https://t.co/MoVYnQV6xR
Aurelie Najm AurelieRheumo ( View Tweet)
Ab0411 #ACR22 Bimekizumab in AS
P3 24 wk PBO control study BE-MOBILE 2
221 BKZ, 111 PBO
Wk 16 ASAS40: BKZ 45%, 22% PBO p<0.001
Efficacy in both TNF naive and TNF failure pts
Wk 24: 1/2 pts has ASDAS<2.1
Nasopharyngitis (6%), diarrhea (4%), h/a (3.6%) 👅candidiasis (3%)
@Rheumnow https://t.co/R1ieW0FB6m
Eric Dein ericdeinmd ( View Tweet)
Mathew et al. Combination biologics from MarketScan. Combination less likely to have ER visit in 180 days 17% vs 23% @RheumNow #ACR22 Abstr#0768 https://t.co/Y880qDXMow https://t.co/gOH2Zlt6UV
Richard Conway RichardPAConway ( View Tweet)
CASIPSA study: retro CT SIJ analysis 48 PsA & age/sex matched ctrls.
JSN, erosion, sclerosis in 1/3 pts w/ peripheral & 1/3 pts w/ axial disease.
PsA > erosions, no diff in other parameters: lack of power or true absence of diff?
https://t.co/CR0LymrinT
Abs#1012 #ACR22 @Rheumnow https://t.co/akYYqbIFNx
Aurelie Najm AurelieRheumo ( View Tweet)
Wang @zach_wallace_md et al. Machine learning can accurately classify clinical note sections as reflecting a diagnosis of AAV. As a machine learning sceptic, data like this helps (slowly) convert me. @RheumNow #ACR22 Abstr#0700 https://t.co/qbq9j9XzXG https://t.co/8iNJElI2vJ
Richard Conway RichardPAConway ( View Tweet)
I typically do not use mepolizumab for "vasculitic" EGPA --> recent ACR/VF guidelines agreed
Interesting study @TerrierBen suggests benefit regardless of ANCA, BVAS, VDI
Have others been using in this context or seen similar?
#ACR22 @RheumNow #ACRBest #1075 https://t.co/C6isdSn2eI
Mike Putman EBRheum ( View Tweet)
Are we really treating Psoriatic disease if we only address active disease domains and T2T? #ACR22
https://t.co/D3F5EzLfeP https://t.co/TO3GyZA6Lb
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR22 Abstr#1654 Press Release #lupus. A cohort study using case-crossover design showed that HCQ dose =<5mg/kg actual body weight OR <400mg/day were associated with increased risk of severe #SLE flare requiring hospitalisation. Need to review Guidelines on HCQ dose @RheumNow https://t.co/5mMh7g6wcA
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Toxic granules in blood vessels may damage vasculature and cause fibrosis around vessels. ‘Occult vascular disease occurs in #scleroderma, don’t forget about it’ says Wigley at Hench Memorial Lecture #ACR22 @RheumNow @ACRheum insights by a humble #SSc leader 🙏🏻 https://t.co/M82p6DwZ6Q
Janet Pope Janetbirdope ( View Tweet)
AURORA 2 data VOC-treated pts w/ pure and mixed Class V lupus nephritis saw reductions in UPCR that occurred faster than in those treated with MMF and low-dose steroids alone. Abs 0355 #ACR22 @RheumNow https://t.co/eHVLDCcti8 https://t.co/jbuiOSqqsa
Dr. Rachel Tate uptoTate ( View Tweet)
Targeting MRI remission in RA, specifically targeting osteitis, did not confer benefit over clinical T2T over 2 years. Maybe our clinical examination is not so bad afterall @steverheum_hall
@RheumNow ABST0890 #ACR22
https://t.co/8nUjWQONyk https://t.co/xGzZNLiJ7U
Julian Segan JulianSegan ( View Tweet)
Meng MA of risk of tapering MTX from combo with bDMARD/tsDMARD in RA in remission. RR 0.90 (95% CI 0.84, 0.97) for maintaining remission over maximum 18 months. Authors conclude little risk to stopping - I disagree 10% is >0. @RheumNow #ACR22 Abstr#0916 https://t.co/9lJXdeVmpg https://t.co/CEV29Mc8uW
Richard Conway RichardPAConway ( View Tweet)
> 50% of SLE pts showed activation of all 3 complement pathways. The most frequent patterns were normal CL, low AL, normal MBL; low CL & AL, normal MBL. Dz activity, not damage, assoc'd only w/low CL and AL, and normal MBL. Abs 0317 #ACR22 @RheumNow https://t.co/nXtuZCfKDI
Dr. Rachel Tate uptoTate ( View Tweet)
Leng et al. 52 week results tocilizumab biosimilar vs originator in RA. Shocker, it's the same. @RheumNow #ACR22 Abstr#0917 https://t.co/5JAoGBRzUi https://t.co/7zCUNcdzbp
Richard Conway RichardPAConway ( View Tweet)
Proliferative LN assoc'd w/ higher risk of IFTA progression, suggesting that glomerular damage is one of the major drivers of IFTA progression in SLE. Abs 0319 #ACR22 @RheumNow https://t.co/CgdXhDBk3e https://t.co/AOZ1DnH6Sk
Dr. Rachel Tate uptoTate ( View Tweet)
Package insert for avacopan has a lot of monitoring requirements, including liver risk, but that seems to be relatively small (2 events per 100 pt-yrs vs pred). Other risks actually favorable as compared to pred
How are others monitoring LFTs?
#ACR22 @RheumNow #1077 https://t.co/VFHCpkQMWN
Mike Putman EBRheum ( View Tweet)
Kim et al. KOBIO study retention rates b/tsDMARDs in RA-ILD. Lower than in RA without ILD. Smoking (OR 5.2) steroids (OR 0.3) influence. JAKi>tocilizumab>abatacept>TNFi @RheumNow #ACR22 Abstr#0920 https://t.co/ht7IFP7VJe https://t.co/Ul93kcdP5N
Richard Conway RichardPAConway ( View Tweet)